Synopsis:- Shares gained 7% after regulatory progress in Azerbaijan and the Philippines boosted sentiment. Expected GMP approval and CPR clearances improve export visibility. With Rs 204 crore H1 mix and margins at 51.35%, expansion into Vietnam and Thailand could drive growth despite short-term pressures.
The shares of this pharmaceutical company gained up to 7 percent in today’s trading session after the company’s manufacturing facility was successfully inspected by the Ministry of Health of the Azerbaijan Republic.
With a market capitalisation of Rs 1,366.05 crore, the shares of Beta Drugs Ltd were trading at Rs 1,347.60 per share, increasing around 2.36 percent as compared to the previous closing price of Rs 1,316.50 apiece.
Regulatory Progress
The shares of Beta Drugs have seen bullish movement after strengthening its global footprint with key regulatory progress in Azerbaijan and the Philippines. The Azerbaijan facility inspection and expected GMP approval within 1–2 months, along with existing EAEU approval, can unlock CIS market opportunities. Meanwhile, the first generic CPR approvals in the Philippines position the company for early entry and improved export visibility.
Furthermore, the company expects additional approvals over the next six months, supporting expansion into Southeast Asia, including Vietnam and Thailand. Building on existing certifications like PIC/S, ANVISA, INVIMA, and EU GMP inspection progress, these developments enhance credibility in regulated markets. Consequently, this should accelerate international filings and drive sustained growth in export revenues.
Financial & other Highlights
The company reported a slight decline in performance, with revenue dipping 1% from Rs 88.29 crore to Rs 87.27 crore. Similarly, net profit fell 5% from Rs 8.95 crore to Rs 8.52 crore, indicating mild pressure on profitability, possibly due to cost factors or weaker operating conditions during the period.
The company’s H1FY26 revenue mix of Rs 204 crore shows strong diversification, led by CDMO at Rs 79 crore, followed by branded oncology at Rs 60 crore and exports at Rs 43 crore. Meanwhile, the API and derma segments contributed smaller shares. This balanced mix highlights multiple growth drivers, though dependence on CDMO remains relatively higher.
However, margins faced slight pressure, with gross margin declining by around 1.5% YoY to 51.35% due to product mix changes. Lower-margin “Platin” products within CDMO impacted profitability despite being less than 7% of revenue. Nevertheless, management maintained EBITDA margin guidance of 23–25%, reflecting confidence in overall operational stability.
Ace investor Ashish Kacholia holds a 12.5% stake in Beta Drugs, amounting to around 12.63 lakh shares valued at nearly Rs 169.2 crore, reflecting strong conviction in the company. Notably, his broader portfolio spans 51 stocks with a net worth exceeding Rs 2,613 crore, highlighting his diversified investment strategy and market confidence.
Beta Drugs Ltd is an India-based pharmaceutical company focused on oncology formulations and specialized therapies. It develops, manufactures, and markets a range of anti-cancer drugs across domestic and international markets. With strong regulatory capabilities and a growing export presence, the company aims to expand its footprint in regulated and emerging markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Can Beta Drugs Boost Exports via Approvals in Azerbaijan and Southeast Asia? appeared first on Trade Brains.